OBJECTIVE: The prevailing hypothesis that early subclinical small-fiber injury precedes large-fiber damage in diabetic sensorimotor polyneuropathy (DSP) is based on lower intraepithelial nerve fiber density in type 2 prediabetic patients despite normal nerve conduction studies (NCSs). We aimed to confirm the same hypothesis in type 1 diabetic patients by examining whether: (1) subjects without DSP include a spectrum with both normal and abnormal small-fiber measures and (2) subjects with DSP have concurrent evidence of abnormal small-fiber measures. RESEARCH DESIGN AND METHODS: A healthy control population (n = 53) was used to generate threshold values for four small-fiber tests: cooling detection thresholds (CDTs), laser Doppler imaging of heat-evoked flare (LDIflare), heart rate variability (HRV), and corneal confocal microscopy. Based on NCS results, type 1 diabetic patients (n = 131) were dichotomized according to the presence or absence of DSP. RESULTS: Threshold values derived from healthy control subjects were 26.5 °C, 1.4 cm2, 13%, and 12.9 mm/mm2 for CDT, LDIflare, HRV, and corneal nerve fiber length, respectively. Among type 1 diabetic patients, 57 of 131 had evidence of DSP, and 74 of 133 did not. Using abnormality of any small-fiber test to define small-fiber dysfunction, 55 of 57 (96.5%) DSP patients and 39 of 74 (52.7%) control subjects without DSP had concurrent small-fiber damage. The severity of small-fiber abnormalities worsened with an increasing number of NCS abnormalities (ANOVA, P < 0.01). CONCLUSIONS: Our findings in type 1 diabetes support the prevailing hypothesis that small-fiber dysfunction occurs early in DSP. However, further research is required to determine which combination of small-fiber tests is most suitable as a surrogate marker in clinical trials.
OBJECTIVE: The prevailing hypothesis that early subclinical small-fiber injury precedes large-fiber damage in diabetic sensorimotor polyneuropathy (DSP) is based on lower intraepithelial nerve fiber density in type 2 prediabeticpatients despite normal nerve conduction studies (NCSs). We aimed to confirm the same hypothesis in type 1 diabeticpatients by examining whether: (1) subjects without DSP include a spectrum with both normal and abnormal small-fiber measures and (2) subjects with DSP have concurrent evidence of abnormal small-fiber measures. RESEARCH DESIGN AND METHODS: A healthy control population (n = 53) was used to generate threshold values for four small-fiber tests: cooling detection thresholds (CDTs), laser Doppler imaging of heat-evoked flare (LDIflare), heart rate variability (HRV), and corneal confocal microscopy. Based on NCS results, type 1 diabeticpatients (n = 131) were dichotomized according to the presence or absence of DSP. RESULTS: Threshold values derived from healthy control subjects were 26.5 °C, 1.4 cm2, 13%, and 12.9 mm/mm2 for CDT, LDIflare, HRV, and corneal nerve fiber length, respectively. Among type 1 diabeticpatients, 57 of 131 had evidence of DSP, and 74 of 133 did not. Using abnormality of any small-fiber test to define small-fiber dysfunction, 55 of 57 (96.5%) DSP patients and 39 of 74 (52.7%) control subjects without DSP had concurrent small-fiber damage. The severity of small-fiber abnormalities worsened with an increasing number of NCS abnormalities (ANOVA, P < 0.01). CONCLUSIONS: Our findings in type 1 diabetes support the prevailing hypothesis that small-fiber dysfunction occurs early in DSP. However, further research is required to determine which combination of small-fiber tests is most suitable as a surrogate marker in clinical trials.
Authors: Xin Chen; Jim Graham; Mohammad A Dabbah; Ioannis N Petropoulos; Georgios Ponirakis; Omar Asghar; Uazman Alam; Andrew Marshall; Hassan Fadavi; Maryam Ferdousi; Shazli Azmi; Mitra Tavakoli; Nathan Efron; Maria Jeziorska; Rayaz A Malik Journal: Diabetes Care Date: 2015-03-20 Impact factor: 19.112
Authors: Nigel A Calcutt; Darrell R Smith; Katie Frizzi; Mohammad Golam Sabbir; Subir K Roy Chowdhury; Teresa Mixcoatl-Zecuatl; Ali Saleh; Nabeel Muttalib; Randy Van der Ploeg; Joseline Ochoa; Allison Gopaul; Lori Tessler; Jürgen Wess; Corinne G Jolivalt; Paul Fernyhough Journal: J Clin Invest Date: 2017-01-17 Impact factor: 14.808
Authors: Daniel Scarr; Leif E Lovblom; Julie A Lovshin; Geneviève Boulet; Mohammed A Farooqi; Andrej Orszag; Alanna Weisman; Nancy Cardinez; Yuliya Lytvyn; Mylan Ngo; Hillary A Keenan; Michael H Brent; Narinder Paul; Vera Bril; David Z I Cherney; Bruce A Perkins Journal: Diabetologia Date: 2017-10-03 Impact factor: 10.122
Authors: Varo Kirthi; Anugraha Perumbalath; Emily Brown; Sarah Nevitt; Ioannis N Petropoulos; Jamie Burgess; Rebecca Roylance; Daniel J Cuthbertson; Timothy L Jackson; Rayaz A Malik; Uazman Alam Journal: BMJ Open Diabetes Res Care Date: 2021-05
Authors: Evan J H Lewis; Bruce A Perkins; Leif E Lovblom; Richard P Bazinet; Thomas M S Wolever; Vera Bril Journal: Neurology Date: 2017-05-17 Impact factor: 9.910